Search results
Showing 61 to 75 of 77 results for psoriasis
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Find out more about NICE technology appraisals advisory committee D members
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
In development Reference number: GID-TA11189 Expected publication date: TBC
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Apremilast for treating moderate to severe plaque psoriasis (TA368)
This guidance has been updated and replaced by NICE technology appraisal guidance 419. The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin...
View recommendations for HTE24Show all sections
Past technology appraisal appeals and decisions
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
In development Reference number: GID-TA11709 Expected publication date: TBC
Biographies and registered interests for members of the Technology Appraisal Committee A